Skip to main
NGNE

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene Inc. is actively advancing its product pipeline focused on genetic medicines for rare neurological diseases, exemplified by NGN-401's impressive results in treating Rett syndrome, where durable, multi-domain improvements have been observed over a 24-month period. The company's expansion of its U.S. clinical footprint to 13 sites reflects a strategic positioning that enhances rapid patient enrollment and meets strong caregiver demand, which could drive greater operational efficiency and patient access. Furthermore, the potential for unforeseen upside in valuation remains as the company has not accounted for any expansion into additional indications beyond NGN-401, suggesting significant growth opportunities as the pipeline develops.

Bears say

Neurogene Inc. faces significant risks that contribute to a negative financial outlook, particularly concerning potential delays in the advancement of its clinical candidates, NGN-401 and NGN-101, through clinical assessments. The company is highly dependent on generating favorable clinical data, especially for NGN-401, targeting Rett syndrome, where any unfavorable results could have dire impacts on both its pipeline and investor confidence. Additionally, there is a looming concern regarding long-term dilution risk for shareholders, which could further hinder the company's financial stability as it seeks to fund ongoing development amidst these uncertainties.

Neurogene Inc (NGNE) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Buy based on their latest research and market trends.

According to 5 analysts, Neurogene Inc (NGNE) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.